Major Basic Science Discovery Is Promising Target for New Diabetes Therapies
NEW YORK, February 8, 2007 – Researchers at Columbia University Medical Center have uncovered the complex structure of a protein that serves as a central energy gauge for cells, providing crucial details about the molecule necessary for developing useful new therapies for diabetes and possibly obesity. A paper published online today in the journal Science details this structure, helping to explain one of the cell’s most basic and critical processes.
An illustration of the AMPK protein
“Understanding this important protein’s molecular structure and mechanism provides a major step forward for the rational design of new drugs to target diabetes and obesity,” said Lawrence Shapiro, Ph.D., associate professor of Biochemistry and Jules and Doris Stein Professor of Research to Prevent Blindness at Columbia University Medical Center, and senior author of the paper.
The protein, known as AMP-activated protein kinase or AMPK, controls metabolic decisions of cells. For example, it controls the decision regarding whether fat is stored or burned, based on the amount of energy in the cell. When the energy level of a cell is high, meaning that the cell contains high amounts of an energy-carrying molecule known as ATP, AMPK directs cells toward “anabolic” activities like storing the extra energy as fat. When ATP is low, AMPK turns off anabolic activities, and activates “catabolic” functions, like burning fat to make energy.
AMPK provides an especially promising drug target for people with type 2 diabetes. These patients are insulin-resistant, meaning that their cells are not responsive to insulin which normally helps glucose get out of the bloodstream, where it does damage, and into cells. When AMPK detects low levels of ATP in the cell, it works through a different mechanism to increase how much glucose the cell takes in and uses to create ATP. Research in rodent models has shown that AMPK activators can lessen the pathologies associated with diabetes, including problems that diabetics have regulating blood sugar.
Dr. Shapiro explained that researchers do not yet know how to activate AMPK without activating other proteins and causing potentially toxic side effects. However, he notes that this development in understanding the atomic resolution structure of the protein provides researchers a powerful new tool for the design of useful therapeutics.
Columbia University Medical Center provides international leadership in pre-clinical and clinical research, in medical and health sciences education, and in patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, nurses, dentists, and public health professionals at the College of Physicians & Surgeons, the College of Dental Medicine, the School of Nursing, the Mailman School of Public Health, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. www.cumc.columbia.edu